Study details
Enrolling now
A Study of Olomorasib (LY3537982) in Healthy Participants
Eli Lilly and Company
NCT IDNCT07439250ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–55
Locations
1 site in FL
About this study
This Phase 1 study is testing Fluconazole in people with healthy volunteers. The primary outcome being measured is Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib.
Based on ClinicalTrials.gov records.
PhasePhase 1
DrugFluconazole
Routeoral
Primary goalPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
fluconazole
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib, Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olomorasib